Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > Patience
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by Alba1314on Jul 20, 2018 10:34am
83 Views
Post# 28344112

RE:Patience

RE:Patience
inthestockgame wrote: Remember we were supposed to get 2 news releases in July...The BIG news that we thought was coming on Monday was not it.  There are lots of good things coming with this company....Patience is all we need to have.  This will spike again soon!!


From NR on June 20th:
 
"We currently expect results from the Phase 1 study in early July 2018."
 
https://web.tmxmoney.com/article.php?newsid=7084357932820863&qm_symbol=ICO
 
Ok, so we got the reults on June 27th. From that NR:
 
""iCo Management waits with anticipation important and material pharmacokinetic data in the coming weeks."
 
ok, so we got that data on July 16:
 
https://web.tmxmoney.com/article.php?newsid=5798260894104632&qm_symbol=ICO
 
Where, in any of that, are you getting a "promise of TWO reports in July"? There's nothing left to report. The trial results are in, and the pharma data has been released. Time to move on. This story is going to take a few years to be told and for now this Phase I chapter is closed.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities